Aligos Therapeutics, Inc. (ALGS) |
|
0.747 0.017 (2.33%)
|
09-29 16:00 |
|
Open: |
0.725 |
Pre. Close: |
0.73 |
|
High:
|
0.7471 |
Low:
|
0.7201 |
|
Volume:
|
25,382 |
Market Cap:
|
32(M) |
|
|
|
Technical analysis |
as of: 2023-09-29 4:25:46 PM |
|
Short-term rate:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 0.98 One year: 1.07 |
| Support: |
Support1: 0.71 Support2: 0.59 |
| Resistance: |
Resistance1: 0.83 Resistance2: 0.91 |
| Pivot: |
0.77  |
| Moving Average: |
MA(5): 0.72 MA(20): 0.79
MA(100): 0.96 MA(250): 1.12 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 12.5 %D(3): 5.7 |
| RSI: |
RSI(14): 34.5 |
| 52-week: |
High: 2.41 Low: 0.71 |
| Average Vol(K): |
3-Month: 69 (K) 10-Days: 46 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ALGS ] has closed above bottom band by 30.5%. Bollinger Bands are 29.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.75 - 0.75 |
0.75 - 0.75 |
|
Low:
|
0.71 - 0.72 |
0.72 - 0.72 |
|
Close:
|
0.74 - 0.75 |
0.75 - 0.75 |
|
Company Description |
|
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California. |
Headline News |
Fri, 22 Sep 2023
Aligos Therapeutics Announces IND Clearance for NASH lead, ALG ... - BioSpace
Thu, 21 Sep 2023
LES ACTIONS AMÉRICAINES EN MOUVEMENT-Fox Corp, Cisco Systems, Darden Restaurants - Boursorama
Thu, 21 Sep 2023
Aligos progresse alors que la FDA autorise le lancement d'essais cliniques pour un médicament contre la NASH - Boursorama
Thu, 03 Aug 2023
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results - Yahoo Finance
Mon, 31 Jul 2023
Checkpoint to sell 3.2M shares at $3.09 in registered direct offering - Seeking Alpha
Wed, 21 Jun 2023
Aligos Therapeutics Presents Data from its Liver Disease Programs ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
40 (M) |
| Shares Float |
18 (M) |
|
% Held by Insiders
|
16.2 (%) |
|
% Held by Institutions
|
67.7 (%) |
|
Shares Short
|
761 (K) |
|
Shares Short P.Month
|
777 (K) |
Stock Financials |
|
EPS
|
-1.93 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.6 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-490.9 |
|
Return on Assets (ttm)
|
-36.7 |
|
Return on Equity (ttm)
|
-79.7 |
|
Qtrly Rev. Growth
|
86.5 |
|
Gross Profit (p.s.)
|
-1.77 |
|
Sales Per Share
|
0.42 |
|
EBITDA (p.s.)
|
-2.05 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-70 (M) |
|
Levered Free Cash Flow
|
-36 (M) |
Stock Valuations |
|
PE Ratio
|
-0.39 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.46 |
|
Price to Sales
|
1.74 |
|
Price to Cash Flow
|
-0.44 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
